Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis.
J Bioenerg Biomembr
; 56(4): 361-371, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38743190
ABSTRACT
Septic cardiomyopathy is a severe cardiovascular disease with a poor prognosis. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to improve ischemia-reperfusion injury by alleviating ferroptosis in cardiomyocyte. However, the role of dapagliflozin in sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced septic cardiomyopathy. Our results indicate that dapagliflozin improved cardiac function in septic cardiomyopathy experimental mice. Mechanistically, dapagliflozin works by inhibiting the translation of key proteins involved in ferroptosis, such as GPX4, FTH1, and SLC7A11. It also reduces the transcription of lipid peroxidation-related mRNAs, including PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Compuestos de Bencidrilo
/
Lipopolisacáridos
/
Ferroptosis
/
Glucósidos
Límite:
Animals
Idioma:
En
Revista:
J Bioenerg Biomembr
Año:
2024
Tipo del documento:
Article
País de afiliación:
China